John Snisarenko - 22 Sep 2021 Form 4 Insider Report for Oyster Point Pharma, Inc.

Role: Chief Commercial Officer
Signature: /s/ Brandon Fenn, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 22 Sep 2021
Net transactions value: $0
Form type: 4
Filing time: 24 Sep 2021, 16:44:25 UTC
Next filing: 04 Nov 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OYST	Employee Stock Option (Right to Buy)	Award	$0	+20,000		$0.000000	20,000	22 Sep 2021	Common Stock	20,000	$12.23	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Option granted on September 22, 2021 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. 1/4th of the options shall vest and become exercisable on August 25, 2022 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2019 Equity Incentive Plan) through each such date.

Content

Option granted on September 22, 2021 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. 1/4th of the options shall vest and become exercisable on August 25, 2022 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2019 Equity Incentive Plan) through each such date.